A Single-Center, Prospective Phase II Clinical Study of Proton Beam Intensity-Modulated Stereotactic Radiotherapy for Early-Stage Non-Small Cell Lung Cancer

Guangzhou Concord Cancer Center

Status: Not yet enrolling

Conditions: Lung Cancer; Early-Stage Lung Cancer

Treatments: Radiation: Stereotactic Body Proton Therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT07412327

2025-IIT-002

Details and patient eligibility

About

This study included patients with early-stage lung cancer cT1-3N0M0, stage IA-IIB (AJCC eighth edition staging) who were inoperable or refused surgery. They were divided into peripheral type and central type according to the tumor location and received radical proton hypofractionated radiotherapy. The prescribed dose for patients with peripheral lung cancer is 48-60Gy(RBE)/4-6 fractions, and for patients with central lung cancer, the prescribed dose is 50-70Gy(RBE)/10-15 fractions. After treatment, follow-up visits will be conducted to observe short-term and long-term efficacy, adverse reactions and patient quality of life.

Enrollment: 65 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. .Lung cancer confirmed by histology and/or cytology; and in the absence of pathological diagnosis, patients who meet the following conditions can also be included: diagnosed by more than 2 imaging modalities, and the clinical diagnosis of lung cancer is confirmed after MDT discussion.
2. The clinical staging based on PET-CT examination is: cT1~3 N0M0, stage IA-IIB (AJCC eighth edition).
3. Age: 18 years and above.
4. KPS score ≥60.
5. The doctor assesses that surgical treatment is not suitable or the patient refuses surgery.
6. Relatively good organ function:
7. Normal bone marrow function: WBC≥3×109/L, Platelet ≥80×109/L, HGB≥90g/L
8. Normal liver and kidney function:
9. Total bilirubin, AST, and ALT≤2.0×upper limit of normal values;
10. Creatinine clearance ≥60ml/min or creatinine ≤1.5×upper limit of normal value
11. The patient has signed an informed consent form and is willing and able to comply with planned study visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

1. Patients with other malignant tumors.
2. Poorly controlled heart failure, respiratory failure, heart function, and lung function below grade 3 (including grade 3).
3. Those whose laboratory test values do not meet relevant standards before enrollment.
4. Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographical reasons.
5. Women of childbearing age who have a positive pregnancy test and women who are breastfeeding.
6. Patients considered inappropriate for inclusion by other investigators.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

65 participants in 1 patient group

Stereotactic Body Proton Therapy

Experimental group

Description:

The prescribed dose for patients with peripheral lung cancer is 48-60Gy(RBE)/4-6 fractions, and for patients with central lung cancer, the prescribed dose is 50-70Gy(RBE)/10-15 fractions.

Treatment:

Radiation: Stereotactic Body Proton Therapy